LMLLF (Pharmadrug) NonCurrent Deferred Revenue: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharmadrug NonCurrent Deferred Revenue?

Pharmadrug LMLLF +0.96% NonCurrent Deferred Revenue is $0.00 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Pharmadrug's non-current deferred revenue for the quarter that ended in Mar. 2026 was $0.00 Mil.

Pharmadrug NonCurrent Deferred Revenue Related Terms

Pharmadrug NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Pharmadrug's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmadrug NonCurrent Deferred Revenue Chart

Pharmadrug Annual Data
Trend Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmadrug Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Pharmadrug (LMLLF) has a NonCurrent Deferred Revenue of $0.00 Mil as of Mar. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Pharmadrug and its competitors.
Is Pharmadrug's NonCurrent Deferred Revenue too high?
Pharmadrug's current NonCurrent Deferred Revenue is $0.00 Mil.
How does Pharmadrug's NonCurrent Deferred Revenue compare to ZTS?
Pharmadrug's NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Pharmadrug and its competitors. Pharmadrug's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmadrug stock overvalued right now?
Based on GuruFocus' analysis, Pharmadrug (LMLLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.01 — trading 84.3% below its estimated fair value. The current NonCurrent Deferred Revenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Pharmadrug (LMLLF), the current NonCurrent Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmadrug Business Description

Other Exchanges PHRX:Canada
Address 130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5K 1H1
Pharmadrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally derived approved drugs. The company's operations comprise of the corporate division in Canada.